UK E-cigarette Industry's Financial Growth Highlighted in New Study

Nov.30.2022
UK E-cigarette Industry's Financial Growth Highlighted in New Study
The UK's e-cigarette industry experienced strong financial growth, increasing by 23.4% from 2017 to 2021, according to a new study.

A recent study in the UK has highlighted the financial growth of the country's electronic cigarette industry.


According to a study conducted by the Centre for Economics and Business Research (CEBR) on behalf of the UK Vaping Industry Association (UKVIA), the electronic cigarette industry grew by 23.4% from 2017 to 2021, adding £251 million in revenue, and reaching £1.325 billion in 2021 alone.


The report also found that when taking into consideration the indirect economic benefits such as supply chain support and the spending power of workers in the e-cigarette industry, the economic impact would double to over 2.8 billion pounds.


In 2021, the number of people in the UK directly and indirectly employed by the e-cigarette industry (including those employed in other areas of the supply chain) was 17,700, while the e-cigarette industry contributed £310 million to the UK's finances through taxation.


The report also examined the broader socio-economic benefits, such as the potential impact of the e-cigarette industry on healthcare. According to Cebr's report, the total healthcare cost savings associated with smokers switching to e-cigarette products in 2019 amounted to £322 million. The research group further stated that "if 50% of smokers switch to e-cigarettes, the potential healthcare cost savings" in 2020 could be £698 million.


Owen Good, the director of economic consulting firm Cebr, stated that the results of the first economic impact report on the vaping industry demonstrate its enormous success as a rapidly growing disruptive industry.


Despite many retail businesses on commercial streets suffering losses in recent years, the electronic cigarette industry has been on an upward trend with significant growth both in-store and online. Even the impact of the pandemic has not significantly hindered the industry's growth.


The growth of this industry is beneficial to the UK economy, companies and their employees engaged directly in the industry, as well as businesses and their employees operating in a wider supply chain. As more and more smokers switch to e-cigarettes to quit smoking, the NHS has also been able to significantly save on costs.


John Dunne, the Secretary-General of UKVIA, explained just how sizable this category is. "In just over a decade, e-cigarettes in the UK have grown from a 'cottage industry' into not only a retail sector, but one of the fastest-growing industries in the entire economy.


More people than ever are using electronic cigarettes, and it is seen as a true success story in the UK. It has created jobs and wealth, generated valuable income for the government through taxation, and by encouraging people to switch from traditional smoking to e-cigarettes, it has saved the NHS over £300 million per year.


2FIRSTS will continue to provide ongoing coverage of this topic, with future updates available on the '2FIRSTS APP'. Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT acquires state-owned shares of UZBAT in Uzbekistan for $22.3 million
BAT acquires state-owned shares of UZBAT in Uzbekistan for $22.3 million
British American Tobacco (BAT) acquires state-owned shares of UZBAT, a joint venture in Uzbekistan, for $22.3 million.
Oct.15 by 2FIRSTS.ai
InterTabac 2025 Insights|BAT Exhibits Full Portfolio, Highlights VUSE Ultra and Introduces Zero-Nicotine Products
InterTabac 2025 Insights|BAT Exhibits Full Portfolio, Highlights VUSE Ultra and Introduces Zero-Nicotine Products
2Firsts’ on-site reporting at InterTabac 2025 in Dortmund, Germany, found that BAT showcased a range of HTP, e-vapor, and nicotine pouch products, with a focus on zero-nicotine e-vapor and the VUSE Ultra line, and set up an interactive experience area.
Sep.19 by 2FIRSTS.ai
PMI Launches VEEV E-Cigarette in South Africa, Expanding Access to Smoke-Free Alternatives
PMI Launches VEEV E-Cigarette in South Africa, Expanding Access to Smoke-Free Alternatives
Philip Morris International's South Africa branch launches e-cigarette product Veev, making South Africa one of 20 countries with PMI's smoke-free products.
Oct.13 by 2FIRSTS.ai
UK busts major illegal e-cigarette case involving 120,000 units; ringleader gets one year in prison
UK busts major illegal e-cigarette case involving 120,000 units; ringleader gets one year in prison
In 2024, UK trading standards uncovered a nationwide illegal e-cigarette supply operation. Business owner Amandeep Kukraja supplied nearly 120,000 illegal products nationwide and received a 12-month probation sentence plus forfeiture of over £300,000 in criminal proceeds.
Sep.12 by 2FIRSTS.ai
Malaysian suspect in illegal e-cigarette trade case in Singapore to appear in court next week for charges including fraud and obstruction of justice
Malaysian suspect in illegal e-cigarette trade case in Singapore to appear in court next week for charges including fraud and obstruction of justice
Malaysian suspect accused of illegal e-cigarette trading in Singapore to face court next week for fraud and obstruction charges.
Sep.15 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai